Triple antiviral treatment started within 7 days of patient indication COVID-19 (New Coronavirus Infection) It was found to be symptomatic, safer than lopinavir, and shortening the duration of viral shedding-Ritonavir Alone (7 days vs. 12 days on average).
May 8 issue of Phase 2 study Lancet The journal did not include patients with serious illness. The researchers emphasized the need for a large phase 3 trial in critically ill patients to determine whether triple therapy has clinically significant benefits.
“Our trial has mild to moderate early treatment COVID-19 (New Coronavirus Infection) Triple combination of antiviral agents Drug By reducing the duration and amount of viral shedding, it may rapidly reduce the amount of virus in the patient’s body, relieve symptoms and reduce the risk to healthcare professionals. [when the virus is detectable and potentially transmissible]”. Dr. Kwok-Yung Yuen, a research leader at the University of Hong Kong, said.
“In addition, the combination of treatments seemed safe and well tolerated by the patient,” he added in a journal news release.
“Despite these promising findings, larger phase 3 trials need to confirm that: interferon Beta 1b alone or in combination with other drugs is effective in patients with more serious illnesses, “says Yuen.
Another expert agreed that the antiviral combo needed further testing.
“Some of these drugs have proven antiviral properties, so it makes sense to test them,” said Dr. Matthew Heinz, a hospitalist at the Tucson Medical Center who helped the United States respond. Told. Ebola The crisis during the Obama administration.
“Lopinavir-ritonavir is an antiretroviral drug used for treatment HIV,and Ribavirin Used for treatment Hepatitis C.. Interferon beta 1b occurs naturally in humans when responding to viral infections such as: influenza Commonly used for treatment Multiple sclerosis,” He said.
However, “this study excluded severe and severely ill patients,” Heinz added. “So we don’t know if we are the most ill COVID-19 (New Coronavirus Infection) Patients will benefit from combination therapy. “
Still, the author of the accompanying commentary said that this trial was COVID-19 (New Coronavirus Infection) processing.
“Most of the studies published so far have been retrospective or observational studies. Therefore, this prospective randomized controlled trial provides remarkable value in increasing therapeutic evidence and is unique to many retrospective studies. We will remove the restrictions, “said Dr. Sarah Sharhaub of Western University. In Canada.
“This study SARS-CoV-2.However, as the authors acknowledge, future studies investigating the efficacy of interferon beta-1b alone or in combination with other drugs to treat severe or severely ill patients. COVID-19 (New Coronavirus Infection) Guaranteed compared to placebo. “
Copyright © 2020 Health Day. all rights reserved.
Source: Dr. Matthew Heinz, MD, Hospitalist, Tucson Medical Center, Arizona. Lancet, News Release, May 8, 2020
Antiviral trio shows energy against COVID-19
Source link Antiviral trio shows energy against COVID-19